202 related articles for article (PubMed ID: 33210562)
41. A simplified prognostic index for chronic lymphocytic leukemia treated with ibrutinib: Results from a multicenter retrospective cohort study.
Gordon MJ; Sitlinger A; Salous T; Alqahtani H; Churnetski M; Rivera X; Wisniewski P; Cohen J; Patel K; Shadman M; Choi M; Hill B; Stephens D; Persky D; Brander D; Danilov AV
Leuk Res; 2020 Feb; 89():106302. PubMed ID: 31982152
[No Abstract] [Full Text] [Related]
42. Cutaneous adverse-events in patients treated with Ibrutinib.
Pileri A; Guglielmo A; Agostinelli C; Evangelista V; Bertuzzi C; Alessandrini A; Bruni F; Starace M; Massi A; Broccoli A; Patrizi A; Zinzani PL; Piraccini BM
Dermatol Ther; 2020 Nov; 33(6):e14190. PubMed ID: 32790083
[TBL] [Abstract][Full Text] [Related]
43. Incidental Richter transformation in chronic lymphocytic leukemia patients during temporary interruption of ibrutinib.
Hampel PJ; Cherng HJ; Call TG; Ding W; Khanlari M; McPhail ED; Miranda RN; Lin P; Tawbi HA; Ferrajoli A; Wierda WG; Jain N; Parikh SA
Blood Adv; 2020 Sep; 4(18):4508-4511. PubMed ID: 32946567
[TBL] [Abstract][Full Text] [Related]
44. Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Coutré SE; Furman RR; Flinn IW; Burger JA; Blum K; Sharman J; Jones J; Wierda W; Zhao W; Heerema NA; Johnson AJ; Tran A; Zhou C; Bilotti E; James DF; Byrd JC; O'Brien S
Clin Cancer Res; 2017 Mar; 23(5):1149-1155. PubMed ID: 28073846
[No Abstract] [Full Text] [Related]
45. Survival adjusting for crossover: phase 3 study of ibrutinib
Coutre S; Tedeschi A; Robak T; Barr PM; Owen C; Bairey O; Burger J; Zhou C; Styles L; James DF; Kipps TJ
Haematologica; 2018 Jun; 103(6):e249-e251. PubMed ID: 29170253
[No Abstract] [Full Text] [Related]
46. Chronic lymphocytic leukemia, autoimmune hemolytic anemia and ibrutinib: a case report and review of the literature.
Molica S; Levato L; Mirabelli R
Leuk Lymphoma; 2016; 57(3):735-7. PubMed ID: 26337717
[No Abstract] [Full Text] [Related]
47. The safety of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia.
Tran PN; O'Brien S
Expert Opin Drug Saf; 2017 Sep; 16(9):1079-1088. PubMed ID: 28627951
[TBL] [Abstract][Full Text] [Related]
48. Zanubrutinib joins the CLL treatment buffet.
Mozas P; Delgado J
Lancet Oncol; 2022 Aug; 23(8):965-967. PubMed ID: 35810752
[No Abstract] [Full Text] [Related]
49. Ibrutinib Use Complicated by Progressive Multifocal Leukoencephalopathy.
Hsiehchen D; Arasaratnam R; Raj K; Froehlich T; Anderson L
Oncology; 2018; 95(5):319-322. PubMed ID: 30045034
[TBL] [Abstract][Full Text] [Related]
50. Prognostic models in chronic lymphocytic leukemia patients receiving ibrutinib therapy: Results of a comparative performance analysis.
Molica S; Baumann T; Giannarelli D
Eur J Haematol; 2021 Mar; 106(3):425-427. PubMed ID: 33190324
[No Abstract] [Full Text] [Related]
51. Ibrutinib-Induced Cardiac Tamponade in Chronic Lymphocytic Leukemia.
Kidoguchi K; Kubato Y; Nishimura Y; Kizuka-Sano H; Kimura S
Turk J Haematol; 2021 Feb; 38(1):83-85. PubMed ID: 33161683
[No Abstract] [Full Text] [Related]
52. Descriptive analysis of dosing and outcomes for patients with ibrutinib-treated relapsed or refractory chronic lymphocytic leukemia in a Canadian centre.
Uminski K; Brown K; Bucher O; Hibbert I; Dhaliwal DH; Johnston JB; Geirnaert M; Dawe DE; Banerji V
Curr Oncol; 2019 Oct; 26(5):e610-e617. PubMed ID: 31708654
[TBL] [Abstract][Full Text] [Related]
53. Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice.
Hampel PJ; Ding W; Call TG; Rabe KG; Kenderian SS; Witzig TE; Muchtar E; Leis JF; Chanan-Khan AA; Koehler AB; Fonder AL; Schwager SM; Slager SL; Shanafelt TD; Kay NE; Parikh SA
Leuk Lymphoma; 2019 Nov; 60(11):2712-2719. PubMed ID: 31014142
[TBL] [Abstract][Full Text] [Related]
54. Ibrutinib Restores Tumor-specific Adaptive Immunity in Chronic Lymphocytic Leukemia.
Zent CS
Clin Cancer Res; 2021 Aug; 27(16):4465-4467. PubMed ID: 34108178
[TBL] [Abstract][Full Text] [Related]
55. Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study.
Jaglowski SM; Jones JA; Nagar V; Flynn JM; Andritsos LA; Maddocks KJ; Woyach JA; Blum KA; Grever MR; Smucker K; Ruppert AS; Heerema NA; Lozanski G; Stefanos M; Munneke B; West JS; Neuenburg JK; James DF; Hall N; Johnson AJ; Byrd JC
Blood; 2015 Aug; 126(7):842-50. PubMed ID: 26116658
[TBL] [Abstract][Full Text] [Related]
56. Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study.
Thompson PA; Lévy V; Tam CS; Al Nawakil C; Goudot FX; Quinquenel A; Ysebaert L; Michallet AS; Dilhuydy MS; Van Den Neste E; Dupuis J; Keating MJ; Meune C; Cymbalista F
Br J Haematol; 2016 Nov; 175(3):462-466. PubMed ID: 27611233
[TBL] [Abstract][Full Text] [Related]
57. Using ibrutinib in earlier lines of treatment results in better outcomes for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Woyach J; Tedeschi A; Munir T; Siddiqi T; Hillmen P; Byrd JC; Ghia P; Mulligan SP; Dai S; Amaya-Chanaga CI; Dean JP; O'Brien SM; Barr PM
Leuk Lymphoma; 2021 Dec; 62(13):3278-3282. PubMed ID: 34384312
[No Abstract] [Full Text] [Related]
58. Early Transformation to Classic Hodgkin Lymphoma in a Chemotherapy-naïve Chronic Lymphocytic Leukemia Patient upon Initial Treatment with Ibrutinib.
Koshiishi M; Odate T; Nakagawa Y; Suzuki J; Kumagai T; Kawashima I; Yamamoto T; Nakajima K; Tanaka M; Oishi N; Kondo T; Kirito K
Intern Med; 2021 Oct; 60(20):3305-3308. PubMed ID: 33896865
[TBL] [Abstract][Full Text] [Related]
59. Atypical primary cutaneous cryptococcosis during ibrutinib therapy for chronic lymphocytic leukemia.
Peri AM; Rossio R; Tafuri F; Benzecry V; Grancini A; Reda G; Bandera A; Peyvandi F
Ann Hematol; 2019 Dec; 98(12):2847-2849. PubMed ID: 31741032
[No Abstract] [Full Text] [Related]
60. Effects of ibrutinib on glucose-lipid metabolism in patients with chronic lymphocytic leukemia (CLL).
Molica S; Lentini M; Zappalà D; Levato L
Leuk Lymphoma; 2020 Nov; 61(11):2778-2780. PubMed ID: 32543252
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]